Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumoursSofie Van Binnebeek, Christophe M. Deroose, Chris Verslype et al.|European Radiology|2015Cited by 98
Inflammation-Based Index and <sup>68</sup>Ga-DOTATOC PET–Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with <sup>90</sup>Y-DOTATOCElin Pauwels, Christophe M. Deroose, Sofie Van Binnebeek et al.|Journal of Nuclear Medicine|2019Cited by 44
Individualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapySofie Van Binnebeek, Christophe M. Deroose, Kristof Baete et al.|European Journal of Nuclear Medicine and Molecular Imaging|2014Cited by 30
Dynamic 68Ga-DOTATOC PET/CT and static image in NET patientsSofie Van Binnebeek, Christophe M. Deroose, Michel Koole et al.|Nuklearmedizin - NuclearMedicine|2016Cited by 10
Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine TumorsVincent Vandecaveye, Christophe M. Deroose, Raphaëla C. Dresen et al.|Radiology Imaging Cancer|2022Cited by 7